Transduction of non-human primate brain with adeno-associated virus serotype 1: vector trafficking and immune response

2008 ◽  
Vol 0 (ja) ◽  
pp. 081212071307053
Author(s):  
Piotr Hadaczek ◽  
John Forsayeth ◽  
Hanna Mirek ◽  
Keith Munson ◽  
John Bringas ◽  
...  
Keyword(s):  
Immune Response ◽  
Adeno Associated Virus ◽  
Primate Brain ◽  
Virus Serotype ◽  
Serotype 1 ◽  
Human Primate

scholarly journals Transduction of Nonhuman Primate Brain with Adeno-Associated Virus Serotype 1: Vector Trafficking and Immune Response

2009 ◽  
Vol 20 (3) ◽  
pp. 225-237 ◽  
Author(s):  
Piotr Hadaczek ◽  
John Forsayeth ◽  
Hanna Mirek ◽  
Keith Munson ◽  
John Bringas ◽  
...  
Keyword(s):  
Immune Response ◽  
Nonhuman Primate ◽  
Adeno Associated Virus ◽  
Primate Brain ◽  
Virus Serotype ◽  
Serotype 1

Herpes Simplex Virus Clearance during Purification of a Recombinant Adeno-associated Virus Serotype 1 Vector

2014 ◽  
pp. 150127063140004
Author(s):  
Guo-jie Ye ◽  
Marina M Scotti ◽  
Darby L Thomas ◽  
Lijun Wang ◽  
David R. Knop ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Adeno Associated Virus ◽  
Virus Clearance ◽  
Virus Serotype ◽  
Serotype 1 ◽  
Simplex Virus

scholarly journals Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain

Gene Therapy ◽  
2013 ◽  
Vol 20 (12) ◽  
pp. 1178-1183 ◽  
Author(s):  
W San Sebastian ◽  
L Samaranch ◽  
G Heller ◽  
A P Kells ◽  
J Bringas ◽  
...  
Keyword(s):  
Virus Type ◽  
Adeno Associated Virus ◽  
Primate Brain ◽  
Human Primate

scholarly journals Structure and Dynamics of Adeno-Associated Virus Serotype 1 VP1-Unique N-Terminal Domain and Its Role in Capsid Trafficking

2013 ◽  
Vol 87 (9) ◽  
pp. 4974-4984 ◽  
Author(s):  
B. Venkatakrishnan ◽  
J. Yarbrough ◽  
J. Domsic ◽  
A. Bennett ◽  
B. Bothner ◽  
...  
Keyword(s):  
Adeno Associated Virus ◽  
Structure And Dynamics ◽  
Terminal Domain ◽  
Virus Serotype ◽  
Serotype 1

Therapeutic Levels of Factor IX Expression Using a Muscle-Specific Promoter and Adeno-Associated Virus Serotype 1 Vector

2004 ◽  
Vol 15 (8) ◽  
pp. 783-792 ◽  
Author(s):  
Yi-Lin Liu ◽  
Federico Mingozzi ◽  
Sol M. Rodriguéz-Colôn ◽  
Sasha Joseph ◽  
Eric Dobrzynski ◽  
...  
Keyword(s):  
Factor Ix ◽  
Adeno Associated Virus ◽  
Virus Serotype ◽  
Serotype 1

scholarly journals OneBac: Platform for Scalable and High-Titer Production of Adeno-Associated Virus Serotype 1–12 Vectors for Gene Therapy

2014 ◽  
Vol 25 (3) ◽  
pp. 212-222 ◽  
Author(s):  
Mario Mietzsch ◽  
Sabrina Grasse ◽  
Catherine Zurawski ◽  
Stefan Weger ◽  
Antonette Bennett ◽  
...  
Keyword(s):  
Gene Therapy ◽  
High Titer ◽  
Adeno Associated Virus ◽  
Virus Serotype ◽  
Serotype 1

Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview

2021 ◽  
Vol 21 ◽  
Author(s):  
Wuh-Liang Hwu ◽  
Shin-Ichi Muramatsu ◽  
Bruria Gidoni-Ben-Zeev
Keyword(s):  
Gene Therapy ◽  
Immune Response ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Acid Decarboxylase ◽  
Adeno Associated Virus ◽  
Amino Acid Decarboxylase ◽  
Virus Serotype ◽  
The Brain ◽  
Decarboxylase Deficiency

: Preexisting immunity to adeno-associated virus (AAV) poses a concern in AAV vector–mediated gene therapy. Localized administration of low doses of carefully chosen AAV serotypes can mitigate the risk of an immune response. This article will illustrate the low risk of immune response to AAV serotype 2 vector–mediated gene therapy to the brain with support from clinical trial data in aromatic L-amino acid decarboxylase deficiency and Parkinson disease.

Sign in / Sign up

Export Citation Format

Share Document